Does olive leaf extract lower blood pressure?

The primary active compound in olive leaf extract is oleuropein, a secoiridoid glycoside that gives the leaves their characteristic bitterness. When absorbed, oleuropein breaks down in the gut and bloodstream into several bioactive metabolites, most notably hydroxytyrosol — one of the most potent natural antioxidants identified to date.⁵

Oleuropein works through several mechanisms simultaneously:

• Vasodilation: It relaxes the smooth muscle cells lining blood vessel walls, reducing peripheral vascular resistance and lowering blood pressure through nitric oxide pathways.
• ACE inhibition: Oleuropein partially inhibits angiotensin-converting enzyme (ACE), the same target as a class of common blood pressure medications, helping prevent the hormonal cascade that raises blood pressure.
• Antimicrobial action: The compound disrupts the integrity of bacterial cell membranes and interferes with viral replication, making it active against a wide range of pathogens.
• NF-kB suppression: It inhibits this master switch of inflammation, reducing the downstream production of pro-inflammatory cytokines.⁴

Blood Pressure: Clinical Evidence

Several clinical trials have tested OLE directly against hypertension. In a landmark randomized controlled trial by Lockyer et al., 60 pre-hypertensive men taking OLE for six weeks showed significant reductions in daytime and 24-hour systolic and diastolic blood pressure compared to placebo³. An earlier twin study — which elegantly controlled for genetics — found that those taking 1000 mg/day of OLE experienced mean systolic reductions of up to 13 mmHg more than those on 500 mg, with LDL cholesterol also falling¹.

Perhaps most striking: a clinical comparison study found that OLE at 500 mg twice daily produced blood pressure reductions comparable to Captopril, a widely used ACE inhibitor medication, in patients with stage-1 hypertension².

Antimicrobial Properties

Oleuropein has demonstrated broad antimicrobial activity in laboratory studies, including against gram-positive and gram-negative bacteria, mycoplasma, and several viruses including influenza and herpes simplex virus. The mechanism involves disrupting bacterial membrane integrity and, in viruses, interfering with cell entry and replication.⁵ While most antimicrobial evidence is from in vitro (laboratory) studies rather than human trials, the antimicrobial tradition of olive leaves in Mediterranean folk medicine has real mechanistic support.

Practical Use

OLE supplements are typically standardized to 20% oleuropein content. Common dosages used in clinical trials range from 500 mg to 1000 mg per day. It's generally well tolerated, though it can cause headaches or mild detox-like symptoms in some people when first starting. Those on blood pressure medications should use it cautiously and with medical supervision given its additive effects.

Whole dried olive leaves can also be steeped as a tea, though extract standardization provides more reliable dosing.

See our olive oil page for information on related compounds from the same tree.

Blood Pressure Reduction

The strongest evidence for OLE is in cardiovascular health. Perrinjaquet-Moccetti et al. (2008, PMID 18729245) conducted an open-label study in 40 borderline hypertensive monozygotic twins — pairs genetically identical — who were assigned to different doses of OLE (500 mg or 1000 mg/day of EFLA943 extract) or lifestyle advice only for 8 weeks. Mean systolic blood pressure differences between twin pairs were ≤6 mmHg (500 mg vs. lifestyle control) and ≤13 mmHg (1000 mg vs. 500 mg). LDL cholesterol was also significantly reduced. The twin design is particularly valuable here as it effectively controls for genetic confounding.

Susalit et al. (2011, PMID 21036583) conducted a randomized, double-blind, parallel, active-controlled trial in patients with stage-1 hypertension. Participants received either OLE (500 mg twice daily) or Captopril (12.5 mg twice daily) for 8 weeks. Both groups showed similar mean systolic blood pressure reductions (~11–13 mmHg) and diastolic reductions (~4–5 mmHg). OLE also produced a significant reduction in LDL cholesterol not seen with Captopril, while Captopril was not superior to OLE in blood pressure control. This head-to-head comparison is notably compelling.

Lockyer et al. (2017, PMID 26951205) ran a randomized, double-blind, placebo-controlled crossover trial in 60 pre-hypertensive males. Participants consumed OLE containing 136 mg oleuropein and 6 mg hydroxytyrosol daily for 6 weeks. Daytime systolic blood pressure was significantly reduced (p < 0.05), as were 24-hour systolic and diastolic readings. The crossover design with washout periods reduces confounding from individual variation.

Anti-Inflammatory Mechanisms

Qabaha et al. (2018, PMID 29099642) investigated which specific components of OLE were responsible for its anti-inflammatory activity. Using LPS-stimulated macrophages, they found that oleuropein at 20 μg/mL was the only OLE fraction demonstrating significant anti-inflammatory activity, while rutin, quercetin, and other isolated components showed no significant effect at comparable concentrations. This clarifies that standardizing to oleuropein content is pharmacologically relevant, not just a marketing claim.

Broad Pharmacological Review

Omar (2010, PMID 21179340) reviewed the emerging pharmacology of oleuropein across antioxidant, anti-inflammatory, anti-atherogenic, antimicrobial, antiviral, and metabolic domains. The review identified in vitro antiviral activity against HIV, influenza, herpes simplex (HSV-1), hepatitis C, and others — noting that HSV-1 replication was inhibited through PKR and transcription factor pathways. Antibacterial mechanisms involve disruption of peptidoglycan synthesis and cell membrane integrity, active against both gram-positive (Staphylococcus) and gram-negative (E. coli, Salmonella) organisms.

Limitations and Strength of Evidence

• Most antimicrobial evidence remains in vitro; robust human trials for infection outcomes are lacking.
• Blood pressure trials are relatively small (n = 40–60) and often of short duration (6–8 weeks).
• Long-term safety data beyond 8 weeks of supplementation in humans is limited.
• Standardization of OLE products varies widely; most clinical trials use proprietary extracts (EFLA943, Olivenol) not necessarily equivalent to commercial products.

Overall, the evidence for blood pressure reduction in pre-hypertensive and stage-1 hypertensive individuals is reasonably well-supported by multiple independent trials. The anti-inflammatory and antimicrobial properties are mechanistically credible but need more clinical trial confirmation. For cardiovascular benefit, OLE represents one of the better-evidenced botanical options with a consistent directional signal across studies.